SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Anonymous 1991 Consensus development conference: Prophylaxis and treatment of osteoporosis. Am J Med 90: 107110.
  • 2
    NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy 2001 March 7–29, 2000: Highlights of the conference. South Med J 94: 569573.
  • 3
    Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev 14: 569573690–709.
  • 4
    Kneissel M, Boyde A, Gasser JA 2001 Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1–34). Bone 28: 237250.
  • 5
    Sato M, Zeng GQ, Turner CH 1997 Biosynthetic human parathyroid hormone (1–34) effects on bone quality in aged ovariectomized rats. Endocrinology 138: 43304337.
  • 6
    Mashiba T, Burr DB, Turner CH, Sato M, Cain RL, Hock JM 2001 Effects of human parathyroid hormone (1–34), LY333334, on bone mass, remodeling, and mechanical properties of cortical bone during the first remodeling cycle in rabbits. Bone 28: 538547.
  • 7
    Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM 2001 Intermittently administered human parathyroid hormone(1–34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16: 157165.
  • 8
    Alexander JM, Bab I, Fish S, Muller R, Uchiyama T, Gronowicz G, Nahounou M, Zhao Q, White DW, Chorev M, Gazit D, Rosenblatt M 2001 Human parathyroid hormone 1–34 reverses bone loss in ovariectomized mice. J Bone Miner Res 16: 16651673.
  • 9
    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30: 312321.
  • 10
    Betancourt M, Wirfel KL, Raymond AK, Yasko AW, Lee J, Vassilopoulou-Sellin R 2003 Osteosarcoma of bone in a patient with primary hyperparathyroidism: A case report. J Bone Miner Res 18: 163166.
  • 11
    Horwitz M, Stewart A, Greenspan SL 2000 Sequential parathyroid hormone/alendronate therapy for osteoporosis—robbing Peter to pay Paul? J Clin Endocrinol Metab 85: 21272128.
  • 12
    Gunness-Hey M, Hock JM 1989 Loss of the anabolic effect of parathyroid hormone on bone after discontinuation of hormone in rats. Bone 10: 447452.
  • 13
    Tanizawa T, Yamamoto N, Takano Y, Mashiba T, Zhang L, Nishida S, Endo N, Takahashi HE, Fujimoto R, Hori M 1998 Effects of human PTH(1–34) and bisphosphonate on the osteopenic rat model. Toxicol Lett 102–103: 399403.
  • 14
    Tang LY, Jee WS, Ke HZ, Kimmel DB 1992 Restoring and maintaining bone in osteopenic female rat skeleton: I. Changes in bone mass and structure. J Bone Miner Res 7: 10931104.
  • 15
    Wronski TJ, Yen CF, Qi H, Dann LM 1993 Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. Endocrinology 132: 823831.
  • 16
    Iwaniec UT, Samnegard E, Cullen DM, Kimmel DB 2001 Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1–84)]-treated rats by estrogen, risedronate, or reduced hPTH. Bone 29: 352360.
  • 17
    Green JR 2001 Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies. Semin Oncol 28: 410.
  • 18
    Ruegsegger P, Koller B, Muller R 1996 A microtomographic system for the nondestructive evaluation of bone architecture. Calcif Tissue Int 58: 2429.
  • 19
    Turner CH 2002 Biomechanics of bone: Determinants of skeletal fragility and bone quality. Osteoporos Int 13: 97104.
  • 20
    Komatsubara S, Mori S, Mashiba T, Ito M, Li J, Kaji Y, Akiyama T, Miyamoto K, Cao Y, Kawanishi J, Norimatsu H 2003 Long-term treatment of incadronate disodium accumulates microdamage but improves the trabecular bone microarchitecture in dog vertebra. J Bone Miner Res 18: 512520.
  • 21
    Frost HM, Jee WS 1992 On the rat model of human osteopenias and osteoporoses. Bone Miner 18: 227236.
  • 22
    Divieti P, Inomata N, Chapin K, Singh R, Juppner H, Bringhurst FR 2001 Receptors for the carboxyl-terminal region of PTH(1–84) are highly expressed in osteocytic cells. Endocrinology 142: 916925.
  • 23
    Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104: 439446.
  • 24
    Shen V, Birchman R, Liang XG, Wu DD, Dempster DW, Lindsay R 1998 Accretion of bone mass and strength with parathyroid hormone prior to the onset of estrogen deficiency can provide temporary beneficial effects in skeletally mature rats. J Bone Miner Res 13: 883890.
  • 25
    Yamamoto N, Takahashi HE, Tanizawa T, Fujimoto R, Hara T, Tanaka S 1993 Maintenance of bone mass by physical exercise after discontinuation of intermittent hPTH(1–34) administration. Bone Miner 23: 333342.
  • 26
    Sato M, Zeng GQ, Rowley E, Turner CH 1998 LY353381 × HCl: An improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1–34). Endocrinology 139: 46424651.